We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer.
- Authors
Nierengarten, Mary Beth
- Abstract
A recent phase 3 trial presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed that the addition of durvalumab and bevacizumab to the standard treatment for unresectable hepatocellular carcinoma (HCC) resulted in significant improvement in progression-free survival (PFS) compared to the standard treatment alone. The study included 616 patients with unresectable HCC and found that the combination treatment was well-tolerated with manageable side effects. While some experts caution that more data is needed before changing standard practice, the results suggest that bevacizumab with immunotherapy may have activity in HCC and should be considered in treatment discussions with patients.
- Subjects
LIVER cancer; CHEMOEMBOLIZATION; BEVACIZUMAB; IMMUNOTHERAPY; BIOMARKERS
- Publication
Cancer (0008543X), 2024, Vol 130, Issue 9, p1547
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35295